Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
08
12
2020
accepted:
30
11
2021
pubmed:
26
1
2022
medline:
23
2
2022
entrez:
25
1
2022
Statut:
ppublish
Résumé
Sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) are the most prevalent monogenic disorders worldwide. Trial HGB-205 ( NCT02151526 ) aimed at evaluating gene therapy by autologous CD34
Identifiants
pubmed: 35075288
doi: 10.1038/s41591-021-01650-w
pii: 10.1038/s41591-021-01650-w
doi:
Banques de données
ClinicalTrials.gov
['NCT02151526', 'NCT02633943', 'NCT04628585']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
81-88Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Cao, A. & Galanello, R. Beta-thalassemia. Genet. Med. 12, 61–76 (2010).
doi: 10.1097/GIM.0b013e3181cd68ed
Pasricha, S. R. & Drakesmith, H. Hemoglobinopathies in the fetal position. N. Engl. J. Med. 379, 1675–1677 (2018).
doi: 10.1056/NEJMcibr1809628
Shah, F. T., Sayani, F., Trompeter, S., Drasar, E. & Piga, A. Challenges of blood transfusions in β-thalassemia. Blood Rev. 37, 100588 (2019).
doi: 10.1016/j.blre.2019.100588
Cappellini, M. D. et al. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia. N. Engl. J. Med. 382, 1219–1231 (2020).
doi: 10.1056/NEJMoa1910182
Niihara, Y. et al. A phase 3 trial of ʟ-glutamine in sickle cell disease. N. Engl. J. Med. 379, 226–235 (2018).
doi: 10.1056/NEJMoa1715971
Vichinsky, E. et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N. Engl. J. Med. 381, 509–519 (2019).
doi: 10.1056/NEJMoa1903212
Ataga, K. I. et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N. Engl. J. Med. 376, 429–439 (2017).
doi: 10.1056/NEJMoa1611770
Bolanos-Meade, J. et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 120, 4285–4291 (2012).
doi: 10.1182/blood-2012-07-438408
Magrin, E., Miccio, A. & Cavazzana, M. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies. Blood 134, 1203–1213 (2019).
doi: 10.1182/blood.2019000949
Imren, S. et al. Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc. Natl Acad. Sci. USA 99, 14380–14385 (2002).
doi: 10.1073/pnas.212507099
Pawliuk, R. et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294, 2368–2371 (2001).
Imren, S. et al. High-level β-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J. Clin. Invest. 114, 953–962 (2004).
doi: 10.1172/JCI200421838
Ronen, K. et al. Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia. Mol. Ther. 19, 1273–1286 (2011).
doi: 10.1038/mt.2011.20
Negre, O. et al. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease. Curr. Gene Ther. 15, 64–81 (2015).
doi: 10.2174/1566523214666141127095336
Takekoshi, K. J., Oh, Y. H., Westerman, K. W., London, I. M. & Leboulch, P. Retroviral transfer of a human beta-globin/delta-globin hybrid gene linked to beta locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease. Proc. Natl Acad. Sci. USA 92, 3014–3018 (1995).
doi: 10.1073/pnas.92.7.3014
Srinivasulu, S. et al. Pair-wise interactions of polymerization inhibitory contact site mutations of hemoglobin-S. Protein J. 25, 503–516 (2006).
doi: 10.1007/s10930-006-9034-3
Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467, 318–322 (2010).
doi: 10.1038/nature09328
Thompson, A. A. et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N. Engl. J. Med. 378, 1479–1493 (2018).
doi: 10.1056/NEJMoa1705342
Ribeil, J. A. et al. Gene therapy in a patient with sickle cell disease. N. Engl. J. Med. 376, 848–855 (2017).
doi: 10.1056/NEJMoa1609677
Nagel, R. L. et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type. N. Engl. J. Med. 312, 880–884 (1985).
doi: 10.1056/NEJM198504043121403
Shannon, C. E. A mathematical theory of communication. Bell Syst. Tech. J. 27, 379–423 (1948). 623–656.
doi: 10.1002/j.1538-7305.1948.tb01338.x
Chao, A. Nonparametric estimation of the number of classes in a population. Scand. J. Stat. 11, 265–270 (1984).
Hebert, N. et al. Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease. Am. J. Hematol. 95, 1235–1245 (2020).
doi: 10.1002/ajh.25937
Eaton, W. A., Hofrichter, J. & Ross, P. D. Editorial: Delay time of gelation: a possible determinant of clinical severity in sickle cell disease. Blood 47, 621–627 (1976).
doi: 10.1182/blood.V47.4.621.621
Imren, S. et al. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc. Natl Acad. Sci. USA 99, 14380–14385 (2002).
doi: 10.1073/pnas.212507099
Henry, E. R. et al. Allosteric control of hemoglobin S fiber formation by oxygen and its relation to the pathophysiology of sickle cell disease. Proc. Natl Acad. Sci. USA 117, 15018–15027 (2020).
doi: 10.1073/pnas.1922004117
Ilboudo, Y. et al. A common functional PIEZO1 deletion allele associates with red blood cell density in sickle cell disease patients. Am. J. Hematol. 93, E362–E365 (2018).
doi: 10.1002/ajh.25245
Philippidis, A. After analysis, Bluebird Bio says vector ‘very unlikely’ cause of acute myeloid leukemia. Hum. Gene Ther. 32, 332–334 (2021).
doi: 10.1089/hum.2021.29159.bfs
https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-lifting-fda-clinical-hold-sickle-cell (2021).
Tisdale, J. F. et al. Updated results from HGB-206 LentiGlobin for Sickle Cell Disease Gene Therapy Study: Group C data and Group A AML case investigation. Abstract 196. American Society of Gene & Cell Therapy Annual Meeting (2021).
Seminog, O. O., Ogunlaja, O. I., Yeates, D. & Goldacre, M. J. Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study. J. R. Soc. Med. 109, 303–309 (2016).
doi: 10.1177/0141076816651037
Brunson, A. et al. Increased risk of leukemia among sickle cell disease patients in California. Blood 130, 1597–1599 (2017).
doi: 10.1182/blood-2017-05-783233
Jones, R. J. & DeBaun, M. R. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood 138, 942–947 (2021).
doi: 10.1182/blood.2021011488
Shimoni, A. et al. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced. Leukemia 27, 829–835 (2013).
doi: 10.1038/leu.2012.299
Thompson, A. A. et al. Resolution of serious vaso-occlusive pain crises and reduction in patient-reported pain intensity: results from the ongoing phase 1/2 HGB-206 group C study of lentiglobin for sickle cell disease (bb1111) gene therapy. https://ash.confex.com/ash/2020/webprogram/Paper134940.html (2020).
Brusson, M. et al. Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategies. https://ash.confex.com/ash/2021/webprogram/Paper151076.html (2021).
Thompson, A. A. et al. Favorable outcomes in pediatric patients in the phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) studies of betibeglogene autotemcel gene therapy for the treatment of transfusion-dependent β-thalassemia. Blood 136, 52–54 (2020).
doi: 10.1182/blood-2020-135857
Nualkaew, T. et al. Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral gene therapy vector for β-thalassemia. Mol. Ther. 29, 2841–2853 (2021).